Garadacimab-gxii—A Novel Prophylactic Treatment for Hereditary Angioedema: A Drug Review
Garadacimab reduces the frequency of HAE attacks with a safety profile comparable with existing prophylactic treatments. Its mechanism of targeting activated factor XII offers an alternative approach to HAE management. Ongoing monitoring and post-marketing data may further define its role in clinical practice.
Authors
- Steven R. Feldman (ORCID: https://orcid.org/0000-0002-0090-6289)
- Omar Raheel
- Anette Bygum
- Kelli M Schindel
- Natalie Behzadpour
- Chenan A. Huang
- Vivian Le
Institutions
- University of Kansas (US)
- University of Southern Denmark (DK)
- Wake Forest University (US)
Publication Details
- Journal
- Annals of Pharmacotherapy
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1177/10600280251405482
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00